ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from Royal Bank of Canada
Royal Bank of Canada reissued their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a report published on Sunday morning, AnalystRatings.com reports. Royal Bank of Canada currently has a $27.00 target price on the biopharmaceutical company’s stock.
Several other research analysts also recently commented on PRQR. ValuEngine downgraded shares of ProQR Therapeutics from a buy rating to a hold rating in a report on Thursday, August 8th. Zacks Investment Research raised shares of ProQR Therapeutics from a sell rating to a hold rating in a report on Wednesday, July 10th. Finally, BidaskClub downgraded shares of ProQR Therapeutics from a sell rating to a strong sell rating in a report on Wednesday, July 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. ProQR Therapeutics has an average rating of Buy and a consensus target price of $28.43.
Shares of NASDAQ:PRQR opened at $8.94 on Friday. The firm has a fifty day moving average price of $8.82. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.51 and a current ratio of 9.51. ProQR Therapeutics has a one year low of $7.20 and a one year high of $24.00. The company has a market cap of $343.61 million, a P/E ratio of -6.93 and a beta of 0.11.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Featured Article: What is a Futures Contract?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.